Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Depreciation and Depletion (2016 - 2017)

Eledon Pharmaceuticals filings provide 5 years of Depreciation and Depletion readings, the most recent being $17000.0 for Q1 2017.

  • On a quarterly basis, Depreciation and Depletion fell 67.92% to $17000.0 in Q1 2017 year-over-year; TTM through Mar 2017 was $135000.0, a 14.01% decrease, with the full-year FY2016 number at $171000.0, up 56.88% from a year prior.
  • Depreciation and Depletion hit $17000.0 in Q1 2017 for Eledon Pharmaceuticals, roughly flat from $17000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $56000.0 in Q4 2015 to a low of $3000.0 in Q4 2013.
  • Median Depreciation and Depletion over the past 5 years was $16500.0 (2015), compared with a mean of $22928.6.
  • Biggest five-year swings in Depreciation and Depletion: surged 1020.0% in 2015 and later plummeted 69.64% in 2016.
  • Eledon Pharmaceuticals' Depreciation and Depletion stood at $3000.0 in 2013, then surged by 66.67% to $5000.0 in 2014, then surged by 1020.0% to $56000.0 in 2015, then plummeted by 69.64% to $17000.0 in 2016, then changed by 0.0% to $17000.0 in 2017.
  • The last three reported values for Depreciation and Depletion were $17000.0 (Q1 2017), $17000.0 (Q4 2016), and $49000.0 (Q3 2016) per Business Quant data.